Abstract
Gene therapy can be considered a method of drug delivery. Gene therapy takes advantage of the host organism's gene transcription/translation machinery to locally produce bioactive substances. Gene therapy has been applied to retinal degeneration caused by dominant mutations such as those in the rhodopsin gene. Successful application of ocular gene therapy has been demonstrated in animal diseases or animal models of human disease. The most encouraging results in the field of ocular gene therapy involve treatment of genetically inherited retinal degenerations occurring in various animal species. Various animal models have been used to test gene therapy applications. One significant advantage of gene therapy delivery of pharmacologic agents is that therapeutic levels are maintained without the need for reinjection or implantation devices. Development of gene therapy as a viable, clinically successful methodology will require demonstration of proof-of-principle in a clinical trial. Initiation of a human clinical trial involving ocular gene therapy should be done cautiouslyāespecially because ocular disease is rarely lethal.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.